What is 5-Amino-1MQ?
5-Amino-1MQ is a selective small-molecule inhibitor of , an enzyme implicated in adipose-tissue metabolic dysregulation.
5-Amino-1MQ — selective NNMT inhibitor
In short
Selective NNMT inhibitor studied in cellular models for its modulation of energy metabolism and NAD+ levels.
Overview
5-Amino-1MQ is a selective small-molecule inhibitor of , an enzyme implicated in adipose-tissue metabolic dysregulation.
5-Amino-1MQ competitively inhibits (IC₅₀ ≈ 1.5 µM), reducing 1-methylnicotinamide accumulation and restoring nicotinamide availability for NAD⁺ salvage. In white-adipose-tissue models the result is enhanced lipolysis, improved insulin sensitivity, and modulation of the methyl/NAD⁺ balance toward a phenotype associated with leaner metabolic profile.
Molecular information
Ограничени данни за човешка безопасност. Йодидната солна форма допринася за йоден товар — протоколите при субекти с достатъчен йоден прием трябва да мониторират тиреоидната функция при удължени цикли. Дългосрочно селективно инхибиране не е характеризирано в човешко изследване; стандартна предпазливост за изследователски съединения се прилага.
2 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Information about 5-Amino-1MQ is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
Adipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadCagrilintide
Cagrilintide is a modified amylin analog developed by Novo Nordisk as a partner to semaglutide in combined incretin-amylin therapy. CagriSema (cagrilintide + semaglutide) showed 17.1% body-weight reduction in Phase 2 — a promising next step over semaglutide alone.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.